https://druganalyst.com/AstraZeneca/Saphnelo
Saphnelo (anifrolumab) - Astra Sales History and Forecasts - DRUGANALYST
sales historysaphneloastraforecasts
https://www.consultantlive.com/view/anifrolumab-saphnelo-wins-fda-approval-for-subcutaneous-self-administration-in-sle
Anifrolumab (Saphnelo) Wins FDA Approval for Subcutaneous Self-Administration in SLE
The FDA approved anifrolumab via a once-weekly subcutaneous autoinjector for moderate to severe SLE based on phase 3 TULIP-SC trial results.
fda approvalsaphnelowins
https://www.lupus.org/news/update-selfadministered-saphnelo-remains-under-fda-review-in-the-us
Update: Self-administered Saphnelo remains under FDA review in the U.S. | Lupus Foundation of...
The U.S. Food and Drug Administration (FDA) issued a complete response letter requesting additional information from AstraZeneca regarding the Biologics...
https://www.1blv.com/drugDetail/1254.html
安尼鲁单抗(Saphnelo)的说明书:适应症,用法用量,不良反应,注意事项_医伴旅
saphnelo
https://www.arthritiscenters.net/therapy/saphnelo-anifrolumab-fnia/
Saphnelo (Anifrolumab-fnia) - Sarasota Arthritis Center
Oct 23, 2023 - The FDA approved Anifrolumab (Saphnelo) in 2021 for the treatment of adult patients with moderate or severe systemic lupus erythematosus.
saphnelosarasotaarthritiscenter